Advances in the diagnosis and treatment of neuroblastoma

Neuroblastoma, a childhood neoplasm arising from neural crest cells, is characterized by a diversity of clinical behavior, ranging from spontaneous remission to rapid tumor progression and death. To some extent, outcome can be predicted by the stage of disease and age at diagnosis. The molecular events responsible for the variability in response to treatment and rate of tumor growth, however, remain largely unknown. Over the past decade, transformation-linked genetic changes have been identified in neuroblastoma tumors that have contributed to our understanding of tumor predisposition, metastasis, treatment responsiveness, and prognosis. This review discusses the recent advances in the understanding of neuroblastoma at the cellular and molecular levels, and the role that tumor biology plays in determining appropriate risk-based treatment for patients with neuroblastoma.

[1]  A. Davidoff,et al.  Humoral response to vaccination with interleukin-2-expressing allogeneic neuroblastoma cells after primary therapy. , 2000, Medical and pediatric oncology.

[2]  W. London,et al.  MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  G. Melino,et al.  Effector mechanisms of fenretinide-induced apoptosis in neuroblastoma. , 2000, Experimental cell research.

[4]  D. Neuberg,et al.  Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. , 2000, Human gene therapy.

[6]  D. Stram,et al.  Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Look,et al.  Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study. , 2000, Journal of pediatric hematology/oncology.

[8]  A. Eggert,et al.  High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  D. Stram,et al.  Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Stram,et al.  Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Groshen,et al.  Integrins αvβ3 and αvβ5 Are Expressed by Endothelium of High-Risk Neuroblastoma and Their Inhibition Is Associated with Increased Endogenous Ceramide , 2000 .

[12]  D. Frappaz,et al.  LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Rademaker,et al.  Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  D. Stram,et al.  Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas , 1999, Oncogene.

[15]  K K Matthay,et al.  The International Neuroblastoma Pathology Classification (the Shimada system) , 1999, Cancer.

[16]  K K Matthay,et al.  Molecular biology of neuroblastoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  F. Speleman,et al.  Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. , 1999, The New England journal of medicine.

[18]  S. Cohn,et al.  Long-term outcome of patients with intraspinal neuroblastoma. , 1999, Medical and pediatric oncology.

[19]  S. Jhanwar,et al.  Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  P. Haber,et al.  Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  W. Gerald,et al.  Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  M. Bernstein,et al.  Topotecan in Pediatric Patients With Recurrent and Progressive Solid Tumors: A Pediatric Oncology Group Phase II Study , 1998, Journal of pediatric hematology/oncology.

[23]  A. Look,et al.  Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Uttenreuther-Fischer,et al.  Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Stram,et al.  Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Hanada,et al.  Spontaneous regression of localized neuroblastoma detected by mass screening. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  D. Frappaz,et al.  Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  D. Bigner,et al.  Bone Marrow–generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors , 1997, The Journal of experimental medicine.

[29]  B. Gallie,et al.  MYCN protein expression as a predictor of neuroblastoma prognosis. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  E. Halperin,et al.  Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Pediatric Oncology Group. , 1997, European journal of cancer.

[31]  T. Klingebiel,et al.  1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party. , 1997, European journal of cancer.

[32]  F. Berthold,et al.  The international neuroblastoma risk groups (INRG): a preliminary report , 1997 .

[33]  L. Robison,et al.  Infant Cancer in the U.S.: Histology‐Specific Incidence and Trends, 1973 to 1992 , 1997, Journal of pediatric hematology/oncology.

[34]  M. Slim,et al.  Prenatally diagnosed neuroblastoma , 1997, Cancer.

[35]  K. Matthay,et al.  A Phase I/IB trial of murine monoclonal anti‐GD2 antibody 14.G2a plus interleukin‐2 in children with refractory neuroblastoma , 1997, Cancer.

[36]  M. Cohen,et al.  CD44 expression in neuroblastoma and related tumors. , 1997, Journal of pediatric hematology/oncology.

[37]  G. Mohapatra,et al.  Targeted expression of MYCN causes neuroblastoma in transgenic mice , 1997, The EMBO journal.

[38]  S. Cohn,et al.  Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. , 1997, Medical and pediatric oncology.

[39]  J. Krischer,et al.  Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  A. Look,et al.  Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. , 1997, Journal of the National Cancer Institute.

[41]  O. Delattre,et al.  N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  S. Påhlman,et al.  The Angiogenesis Inhibitor TNP-470 Reduces the Growth Rate of Human Neuroblastoma in Nude Rats , 1997, Pediatric Research.

[43]  M. Ziegler,et al.  TNP-470 antiangiogenic therapy for advanced murine neuroblastoma. , 1997, Journal of pediatric surgery.

[44]  J. García,et al.  High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: pilot study. , 1996, Medical and pediatric oncology.

[45]  J. García,et al.  Interleukin-2 in neuroblastoma: clinical perspectives based on biological studies. , 1996, Cancer biotherapy & radiopharmaceuticals.

[46]  C. Dominici,et al.  Expression of mRNA for the neurotrophin receptor trkC in neuroblastomas with favourable tumour stage and good prognosis. , 1996, British Journal of Cancer.

[47]  T. Rebbeck,et al.  Familial predisposition to neuroblastoma does not map to chromosome band 1p36. , 1996, Cancer research.

[48]  J. Becker,et al.  An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[49]  D. Frappaz,et al.  The treatment of neuroblastoma with intraspinal extension with chemotherapy followed by surgical removal of residual disease: A prospective study of 42 patients‐‐Results of the NBL 90 study of the French Society of Pediatric Oncology , 1996, Cancer.

[50]  W. Gerald,et al.  International neuroblastoma staging system stage 1 neuroblastoma: a prospective study and literature review. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  A. Rademaker,et al.  Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  W. Gerald,et al.  Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  S. Cohn,et al.  Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. , 1996, The New England journal of medicine.

[54]  Rogier Versteeg,et al.  Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. , 1996, The New England journal of medicine.

[55]  A. Nakagawara,et al.  Expression of TrkC in favorable human neuroblastomas. , 1996, Oncogene.

[56]  F. Berthold,et al.  The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. , 1995, Cancer research.

[57]  A. Look,et al.  Significance of chromosome 1p loss of heterozygosity in neuroblastoma. , 1995, Cancer research.

[58]  D. Stram,et al.  Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. , 1995, Journal of the National Cancer Institute.

[59]  P. D. de Alarcon,et al.  Neuroblastoma-associated opsoclonus-myoclonus treated with intravenously administered immune globulin G. , 1995, The Journal of pediatrics.

[60]  R. Hanada,et al.  Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  K. Matthay,et al.  Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  A. Look,et al.  Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study. , 1995, Cancer research.

[63]  D. Stram,et al.  Surgical management and outcome of locoregional neuroblastoma: comparison of the Childrens Cancer Group and the international staging systems. , 1995, Journal of pediatric surgery.

[64]  W. Gerald,et al.  Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  J. Shuster,et al.  The Pediatric Oncology Group experience with the international staging system criteria for neuroblastoma. Member Institutions of the Pediatric Oncology Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  S. Cohn,et al.  Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma. , 1994, The Journal of pediatrics.

[67]  N. Gross,et al.  Altered growth and phenotype in clonal mycN transfectants of the sk‐n‐sh neuroblastoma cell line , 1994, International journal of cancer.

[68]  C. Manohar,et al.  The biological effects of antisense N-myc expression in human neuroblastoma. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[69]  A. Nakagawara,et al.  Expression and function of TRK-B and BDNF in human neuroblastomas , 1994, Molecular and cellular biology.

[70]  J. Schiller,et al.  Activation of multiple effector mechanisms to enhance tumor immunotherapy. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[71]  D. Stram,et al.  Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  J. Estroff,et al.  Prenatal detection of neuroblastoma: a ten-year experience from the Dana-Farber Cancer Institute and Children's Hospital. , 1993, Pediatrics.

[73]  F. Berthold,et al.  Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. , 1993, Progress in clinical and biological research.

[74]  C. Dominici,et al.  Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. , 1993, Cancer research.

[75]  A. Cantor,et al.  Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. , 1993, The New England journal of medicine.

[76]  D. Stram,et al.  Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. , 1993, Journal of the National Cancer Institute.

[77]  R. Reisfeld,et al.  A mechanism for neutrophil-mediated lysis of human neuroblastoma cells. , 1993, Cancer research.

[78]  M. Nishi,et al.  Mass screening of neuroblastoma in Sapporo City, Japan. , 1992, The American journal of pediatric hematology/oncology.

[79]  C. Raffel Spinal cord compression by epidural tumors in childhood. , 1992, Neurosurgery clinics of North America.

[80]  J. Shuster,et al.  Serum Lactate Dehydrogenase in Childhood Neuroblastoma A Pediatric Oncology Group Recursive Partitioning Study , 1992, American journal of clinical oncology.

[81]  N. Berger,et al.  Reassessment of patient response to monoclonal antibody 3F8. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  M. Arima,et al.  Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. , 1992, Cancer research.

[83]  S. Ferrari,et al.  Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line. , 1991, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[84]  T. Yokoyama,et al.  Immunohistochemical analysis of N-myc protein expression in neuroblastoma: correlation with prognosis of patients. , 1991, Journal of pediatric surgery.

[85]  J. Zucker,et al.  Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: is cure possible in a small subgroup? , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  R. Hoover,et al.  Therapeutic radiation at a young age is linked to secondary thyroid cancer. The Late Effects Study Group. , 1991, Cancer research.

[87]  G. Heller,et al.  Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  A T Look,et al.  Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  J. Silber,et al.  Models to predict outcome from childhood neuroblastoma: the role of serum ferritin and tumor histology. , 1991, Cancer research.

[90]  M. LaQuaglia,et al.  Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  Y. Kaneko,et al.  Current urinary mass screening for catecholamine metabolites at 6 months of age may be detecting only a small portion of high-risk neuroblastomas: a chromosome and N-myc amplification study. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  M. Schwab,et al.  Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity. , 1990, Cancer research.

[93]  J. Locker,et al.  A comparative analysis of nuclear DNA content and N‐myc gene amplification in neuroblastoma , 1990, Cancer.

[94]  A. Rademaker,et al.  Analysis of DNA ploidy and proliferative activity in relation to histology and N-myc amplification in neuroblastoma. , 1990, The American journal of pathology.

[95]  J. Folkman What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[96]  M. Favrot,et al.  A phase-II study of adoptive immunotherapy with continuous infusion of interleukin-2 in children with advanced neuroblastoma. A report on 11 cases. , 1989, Cancer treatment reviews.

[97]  N C Dracopoli,et al.  Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[98]  K. Matthay,et al.  Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  P. Waber,et al.  N-myc oncogene RNA expression in neuroblastoma. , 1988, Journal of the National Cancer Institute.

[100]  C. R. Pinkerton,et al.  International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma. , 1988, Progress in clinical and biological research.

[101]  K. Matthay,et al.  Complete pathologic maturation and regression of stage ivs neuroblastoma without treatment , 1988, Cancer.

[102]  J. Shuster,et al.  Localized neuroblastoma treated by surgery: a Pediatric Oncology Group Study. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  D. Munn,et al.  Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. , 1987, Cancer research.

[104]  K. Propert,et al.  Prognostic factors in neuroblastoma , 1987 .

[105]  T. Gansler,et al.  Flow cytometric DNA analysis of neuroblastoma. Correlation with histology and clinical outcome , 1986, Cancer.

[106]  B. Kushner,et al.  Familial neuroblastoma. Case reports, literature review, and etiologic considerations , 1986, Cancer.

[107]  H. Sather,et al.  Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. , 1985, The New England journal of medicine.

[108]  T. Sawada,et al.  MASS SCREENING FOR NEUROBLASTOMA IN INFANTS IN JAPAN Interim Report of a Mass Screening Study Group , 1984, The Lancet.

[109]  H. B. Marsden,et al.  Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. , 1984, Journal of the National Cancer Institute.

[110]  A. Look,et al.  Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. , 1984, The New England journal of medicine.

[111]  T. Matsumura,et al.  Neuroblastoma. Mass screening for early detection and its prognosis , 1984, Cancer.

[112]  H. Varmus,et al.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. , 1984, Science.

[113]  A. Ruusala,et al.  Retinoic acid-induced differentiation of cultured human neuroblastoma cells: a comparison with phorbolester-induced differentiation. , 1984, Cell differentiation.

[114]  A. Green,et al.  Chemotherapy as an alternative to laminectomy and radiation in the management of epidural tumor. , 1984, The Journal of pediatrics.

[115]  N. Sidell,et al.  Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. , 1982, Journal of the National Cancer Institute.

[116]  A. Evans,et al.  Serum ferritin as a guide to therapy in neuroblastoma. , 1980, Cancer research.

[117]  J. Hutter,et al.  Opsomyoclonus and Neuroblastoma , 1979, Clinical pediatrics.

[118]  N. Jaffe,et al.  Prognosis for children with neuroblastoma presenting with paralysis. , 1977, Journal of pediatric surgery.

[119]  A. Evans,et al.  Spontaneous regression of neuroblastoma. , 1976, National Cancer Institute monograph.

[120]  D. King,et al.  Dumbbell neuroblastomas in children. , 1975, Archives of surgery.

[121]  N. Breslow,et al.  Statistical estimation of prognosis for children with neuroblastoma. , 1971, Cancer research.

[122]  C E Koop,et al.  Special pattern of widespread neuroblastoma with a favourable prognosis. , 1971, Lancet.

[123]  A. Evans,et al.  A proposed staging for children with neuroblastoma. Children's cancer study group A , 1971, Cancer.

[124]  D. Stram,et al.  Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[125]  L. Ries,et al.  Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. , 1999 .

[126]  K. Matthay,et al.  Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. , 1999, The New England journal of medicine.

[127]  S. Lipshultz,et al.  Anthracycline-induced cardiotoxicity in children and young adults. , 1998, Critical reviews in oncology/hematology.

[128]  B. Hasegawa,et al.  Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  P. Bruzzi,et al.  MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[130]  M. Kirpekar,et al.  Spontaneous resolution of antenatally diagnosed adrenal masses. , 1996, Journal of pediatric surgery.

[131]  D. Frappaz,et al.  Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[132]  M. Barbacid Neurotrophic Factors and Their Receptors , 1995, Bio/Technology.

[133]  D. Frappaz,et al.  Evaluation of CD44 prognostic value in neuroblastoma: comparison with the other prognostic factors. , 1995, European journal of cancer.

[134]  H. Jürgens,et al.  Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  G. Brodeur,et al.  Prenatal detection of neuroblastoma by fetal ultrasonography. , 1994, The American journal of pediatric hematology/oncology.

[136]  J. Murray,et al.  Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[137]  C. Sainte-Rose,et al.  Localized dumbbell neuroblastoma: a study of 25 cases treated between 1982 and 1987 using the same protocol. , 1993, Medical and pediatric oncology.

[138]  C. Reynolds,et al.  13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: report from the Childrens Cancer Study Group. , 1992, Medical and pediatric oncology.

[139]  J. Bourhis,et al.  Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. , 1991, Progress in clinical and biological research.

[140]  R. Seeger,et al.  Expression of GD2 ganglioside by untreated primary human neuroblastomas. , 1986, Cancer research.

[141]  H. Sather,et al.  Prognostic importance of serum neuron specific enolase in local and widespread neuroblastoma. , 1985, Progress in clinical and biological research.

[142]  M. Israel,et al.  Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma , 1985, Nature.

[143]  C. Pratt,et al.  Metastatic epidural tumors in children. , 1982, Medical and pediatric oncology.

[144]  B. Bernardi,et al.  © 1999 Cancer Research Campaign Article no. bjoc.1999.0855 , 2022 .